Accordingly, NK-1R antagonists (e.g., aprepitant) have been suggested to treat tumors, including gliomas [62], and hence, the substance P/NK-1R system is a promising antitumor target to treat gliomas. This evidence concerns the gene TACR1 and central nervous system cancer.